tiprankstipranks
Cytek Biosciences, Inc. (DE:8EQ)
NASDAQ:8EQ
Germany Market
8EQ
Cytek Biosciences
RESEARCH TOOLSreports

Cytek Biosciences (8EQ) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

8EQ Analyst Ratings

Moderate Buy
4Ratings
Moderate Buy
2 Buy
2 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Cytek
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

8EQ Stock 12 Month Forecast

Average Price Target

€4.90
▲(26.92% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Cytek Biosciences in the last 3 months. The average price target is €4.90 with a high forecast of €6.46 and a low forecast of €4.09. The average price target represents a 26.92% change from the last price of €3.86.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","4":"€4","7":"€7","2.5":"€2.5","5.5":"€5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.46052145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.89922876625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.091663585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.54,3.7646554961538463,3.989310992307692,4.213966488461539,4.438621984615384,4.6632774807692305,4.887932976923077,5.112588473076923,5.337243969230769,5.561899465384615,5.786554961538462,6.011210457692307,6.235865953846154,{"y":6.46052145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.54,3.6445560589423076,3.7491121178846156,3.853668176826923,3.9582242357692308,4.062780294711539,4.167336353653846,4.271892412596154,4.3764484715384615,4.481004530480769,4.585560589423077,4.690116648365385,4.794672707307693,{"y":4.89922876625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.54,3.5824356603846153,3.624871320769231,3.667306981153846,3.709742641538462,3.752178301923077,3.794613962307692,3.837049622692308,3.879485283076923,3.9219209434615383,3.964356603846154,4.00679226423077,4.049227924615384,{"y":4.091663585,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€6.46Average Price Target€4.90Lowest Price Target€4.09
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on DE:8EQ
Mason Carrico
Stephens
Stephens
€4.09
Buy
6.00%
Upside
Assigned
05/13/26
Cytek Biosciences price target lowered to $4.75 from $5.50 at StephensCytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
Morgan Stanley Analyst forecast on DE:8EQ
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
€4.74
Hold
22.74%
Upside
Assigned
05/12/26
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan StanleyCytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
Piper Sandler Analyst forecast on DE:8EQ
David Westenberg
Piper Sandler
Piper Sandler
€6.46
Buy
67.37%
Upside
Reiterated
05/08/26
Piper Sandler Sticks to Its Buy Rating for Cytek Biosciences (CTKB)
TD Cowen Analyst forecast on DE:8EQ
Brendan Smith
TD Cowen
TD Cowen
€4.31
Hold
11.58%
Upside
Reiterated
05/07/26
Cytek Maintained at Hold as Risk‑Reward Stays Balanced; $5 Price Target Reaffirmed
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on DE:8EQ
Mason Carrico
Stephens
Stephens
€4.09
Buy
6.00%
Upside
Assigned
05/13/26
Cytek Biosciences price target lowered to $4.75 from $5.50 at StephensCytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
Morgan Stanley Analyst forecast on DE:8EQ
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
€4.74
Hold
22.74%
Upside
Assigned
05/12/26
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan StanleyCytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
Piper Sandler Analyst forecast on DE:8EQ
David Westenberg
Piper Sandler
Piper Sandler
€6.46
Buy
67.37%
Upside
Reiterated
05/08/26
Piper Sandler Sticks to Its Buy Rating for Cytek Biosciences (CTKB)
TD Cowen Analyst forecast on DE:8EQ
Brendan Smith
TD Cowen
TD Cowen
€4.31
Hold
11.58%
Upside
Reiterated
05/07/26
Cytek Maintained at Hold as Risk‑Reward Stays Balanced; $5 Price Target Reaffirmed
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytek Biosciences

3 Months
David WestenbergPiper Sandler
Success Rate
11/29 ratings generated profit
38%
Average Return
-1.59%
Copying David Westenberg's trades and holding each position for 3 Months would result in 37.93% of your transactions generating a profit, with an average return of -1.59% per trade.
1 Year
David WestenbergPiper Sandler
Success Rate
5/29 ratings generated profit
17%
Average Return
-17.79%
Copying David Westenberg's trades and holding each position for 1 Year would result in 17.24% of your transactions generating a profit, with an average return of -17.79% per trade.
2 Years
David WestenbergPiper Sandler
Success Rate
2/29 ratings generated profit
7%
Average Return
-28.42%
Copying David Westenberg's trades and holding each position for 2 Years would result in 6.90% of your transactions generating a profit, with an average return of -28.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

8EQ Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
1
1
1
1
Buy
1
0
0
1
1
Hold
3
2
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
3
2
4
4
In the current month, 8EQ has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 8EQ average Analyst price target in the past 3 months is 4.90.
Each month's total comprises the sum of three months' worth of ratings.

8EQ Financial Forecast

8EQ Earnings Forecast

Next quarter’s earnings estimate for 8EQ is -€0.07 with a range of -€0.08 to -€0.07. The previous quarter’s EPS was -€0.13. 8EQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 8EQ has Performed in-line its overall industry.
Next quarter’s earnings estimate for 8EQ is -€0.07 with a range of -€0.08 to -€0.07. The previous quarter’s EPS was -€0.13. 8EQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 8EQ has Performed in-line its overall industry.

8EQ Sales Forecast

Next quarter’s sales forecast for 8EQ is €41.87M with a range of €40.23M to €43.85M. The previous quarter’s sales results were €38.02M. 8EQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 8EQ has Performed in-line its overall industry.
Next quarter’s sales forecast for 8EQ is €41.87M with a range of €40.23M to €43.85M. The previous quarter’s sales results were €38.02M. 8EQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 8EQ has Performed in-line its overall industry.

8EQ Stock Forecast FAQ

What is DE:8EQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytek Biosciences, Inc.’s 12-month average price target is 4.90.
    What is DE:8EQ’s upside potential, based on the analysts’ average price target?
    Cytek Biosciences, Inc. has 26.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Cytek Biosciences, Inc. a Buy, Sell or Hold?
          Cytek Biosciences, Inc. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Cytek Biosciences, Inc.’s share price target?
            The average share price target for Cytek Biosciences, Inc. is 4.90. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €6.46 ,and the lowest forecast is €4.09. The average share price target represents 26.92% Increase from the current price of €3.86.
              What do analysts say about Cytek Biosciences, Inc.?
              Cytek Biosciences, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Cytek Biosciences, Inc.?
                To buy shares of DE:8EQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.